11 Jun

CARBAMAZEPINE

vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

DRUGS/ TDM/ TOXICOLOGY

Synonyms/Aliases

TEGRETOL

Abbreviations

N/A

Type

INDIVIDUAL TEST

Results

RESULTS READY/ REPORTED IN 5 WORKING DAYS

Method

IMMUNOASSAY

Temp

REFRIGERATED

Setup

BATCHED

Components Parameters

NOT APPLICABLE

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. DETAILED SPECIFIC HISTORY IS REQUIRED E.G. EXACT INDICATION FOR DRUG MONITORING, DRUG HISTORY (I.E. DOSE, ROUTE OF ADMINISTRATION, DURATION SINCE TREATMENT WAS STARTED OR DOSE ADJUSTED, CONCURRENT MEDICATION), HEIGHT, WEIGHT.

Patient preparation

SPECIFIC TIMING APPLIES I.E. COLLECT TROUGH (PRE-DOSE) SAMPLE.

Sample type

SERUM

Container/ preservative

PLAIN (RED TOP) VACUTAINER. SERUM SEPARATOR TUBES (SST/ GEL) ARE UNACCEPTABLE.

Sample volume

AT LEAST 2ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE (INCLUDING SST/ GEL TUBES); INSUFFICIENT SAMPLE; MISSING HISTORY AS EXPOUNDED UNDER TEST ORDERING INSTRUCTIONS..

Other Instructions

CENTRIFUGE SST (SERUM GEL TUBES) WITHIN 1-2 HOURS OF COLLECTION. CENTRIFUGE RED TOP VACUTAINERS AND ALIQUOT SERUM WITHIN 1-2 HOURS OF COLLECTION. THE SEPARATION VIAL MUST BE LABELED WITH AT LEAST 2 PATIENT IDENTIFIERS AND THE SAMPLE TYPE.

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

OPTIMIZE DRUG DOSAGE (TO AVOID SUBTHERAPEUTIC & TOXIC DOSES I.E. ENSURE TARGET THERAPEUTIC RANGE IS ACHIEVED); TO VERIFY COMPLIANCE. CARBAMAZEPINE IS AN ANTI-EPILEPTIC (ANTI-CONVULSANT) DRUG.

Test Limitations/ Confounders

LEVELS ARE INFLUENCED BY DOSAGE REGIMEN, DRUG INTERACTIONS, INDIVIDUAL'S METABOLIZING CAPACITY, LIVER DYSFUNCTION. SST/ GEL TUBES CAN ADSORB THE DRUG LEADING TO FALSELY LOWERED DRUG LEVELS & SHOULD BE AVOIDED.
11 Jun

CALPROTECTIN

vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

INFLAMMATION

Synonyms/Aliases

FECAL CALPROTECTIN; FAECAL CALPROTECTIN; STOOL CALPROTECTIN.

Abbreviations

N/A

Type

INDIVIDUAL TEST

Results

RESULTS READY/ REPORTED IN 5 WORKING DAYS

Method

IMMUNOASSAY

Temp

REFRIGERATED OR FROZEN.

Setup

BATCHED

Components Parameters

NOT APPLICABLE

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

NO PREPARATION REQUIRED

Sample type

STOOL (FIRST MORNING STOOL SAMPLE PREFERRED)

Container/ preservative

LEAK PROOF CONTAINER.

Sample volume

100 GMS OF STOOL IN LEAK PROOF CONTAINER.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE..

Other Instructions

-N/A

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

A SENSITIVE MARKER OF GASTROINTESTINAL INFLAMMATION AND IS AN IMPORTANT TEST FOR DIFFERENTIATING INFLAMMATORY BOWEL DISEASE (IBD) E.G. ULCERATIVE COLITIS, CROHN'S DISEASE FROM FUNCTIONAL GUT DISORDERS SUCH AS IRRITABLE BOWEL SYNDROME (IBS). IT MAY BE USED TO DETERMINE THE NEED FOR ENDOSCOPY IN PATIENTS SUSPECTED TO HAVE IBD.

Test Limitations/ Confounders

LEVELS MAY ALSO BE INCREASED BY OTHER CAUSES E.G. GASTROINTESTINAL MALIGNANCIES, POLYPS, INFECTIOUS GASTROENTERITIS, USE OF NSAIDs ETC.
11 Jun

CALCITONIN

vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

ENDOCRINE; TUMOR MARKER

Synonyms/Aliases

THYROCALCITONIN

Abbreviations

N/A

Type

INDIVIDUAL TEST

Results

RESULTS READY/ REPORTED IN 5 WORKING DAYS

Method

IMMUNOASSAY

Temp

FROZEN PREFERRED. AMBIENT (ROOM) TEMPERATURE NOT ACCEPTABLE.

Setup

BATCHED

Components Parameters

NOT APPLICABLE

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

NO PREPARATION REQUIRED

Sample type

SERUM

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 2ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE. SAMPLE(S) NOT FROZEN

Other Instructions

CENTRIFUGE SST (SERUM GEL TUBES) WITHIN 1-2 HOURS OF COLLECTION. CENTRIFUGE RED TOP VACUTAINERS AND ALIQUOT SERUM WITHIN 1-2 HOURS OF COLLECTION. THE SEPARATION VIAL MUST BE LABELED WITH AT LEAST 2 PATIENT IDENTIFIERS AND THE SAMPLE TYPE.

Reference intervals

APPROPRIATE VALUES ARE PROVIDED ON THE REPORT.

Clinical Utility

AN ADJUNCT IN DIAGNOSIS OF MEDULLARY THYROID CANCER (C CELL CARCINOMA). MONITORING TREATMENT RESPONSE, DISEASE PROGRESSION & ASSESSING RECURRENCE IN MEDULLARY THYROID CANCER. LEVELS MAY ALSO BE ELEVATED IN OTHER CANCERS E.G. LUNG CANCER, MYELOPROLIFERATIVE NEOPLASMS, LEUKEMIAS ETC. SCREEN PEOPLE WITH A FAMILY HISTORY OF MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2).

Test Limitations/ Confounders

LEVELS MAY BE ELEVATED IN MULTIPLE BENIGN CONDITIONS E.G. AUTOIMMUNE THYROIDITIS, C-CELL HYPERPLASIA, HYPERCALCEMIA, ALCOHOLISM, RENAL INSUFFICIENCY ETC. IMMUNOASSAY INTERFERENCE CAN GIVE RISE TO SPURIOUS RESULTS. SUCH INTERFERENCE CAN ARISE FROM PRESENCE OF HETEROPHILE ANTIBODIES, ANTI-ANIMAL ANTIBODIES, AUTOANTIBODIES, PARAPROTEINS, BIOTIN ETC. RESULTS SHOULD ALWAYS BE CORRELATED WITH CLINICAL FINDINGS.
11 Jun

CANCER ANTIGEN 19-9

vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

TUMOR MARKER

Synonyms/Aliases

CARBOHYDRATE ANTIGEN 19-9

Abbreviations

CA 19-9

Type

INDIVIDUAL TEST

Results

RESULTS READY/ REPORTED IN 3 HOURS

Method

IMMUNOASSAY

Temp

REFRIGIRATED

Setup

DAILY

Components Parameters

NOT APPLICABLE

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

NO PREPARATION REQUIRED

Sample type

SERUM

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 2ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

CENTRIFUGE SST (SERUM GEL TUBES) WITHIN 1-2 HOURS OF COLLECTION. CENTRIFUGE RED TOP VACUTAINERS AND ALIQUOT SERUM WITHIN 1-2 HOURS OF COLLECTION. THE SEPARATION VIAL MUST BE LABELED WITH AT LEAST 2 PATIENT IDENTIFIERS AND THE SAMPLE TYPE.

Reference intervals

APPROPRIATE VALUES ARE PROVIDED ON THE REPORT.

Clinical Utility

AN ADJUNCT IN DIAGNOSIS OF PANCREATIC CANCER. MONITORING TREATMENT RESPONSE, DISEASE PROGRESSION & ASSESSING RECURRENCE IN PANCREATIC CANCER. LEVELS MAY ALSO BE ELEVATED IN OTHER CANCERS E.G. GALL BLADDER, COLORECTAL, UTERINE ETC.

Test Limitations/ Confounders

LEVELS MAY BE ELEVATED IN MULTIPLE BENIGN CONDITIONS E.G. HEPATITIS, PANCREATITIS, GALL STONES ETC. IMMUNOASSAY INTERFERENCE CAN GIVE RISE TO SPURIOUS RESULTS. SUCH INTERFERENCE CAN ARISE FROM PRESENCE OF HETEROPHILE ANTIBODIES, ANTI-ANIMAL ANTIBODIES, AUTOANTIBODIES, PARAPROTEINS, BIOTIN ETC. RESULTS SHOULD ALWAYS BE CORRELATED WITH CLINICAL FINDINGS.
11 Jun

CANCER ANTIGEN 15-3

vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

TUMOR MARKER

Synonyms/Aliases

CARBOHYDRATE ANTIGEN 15-3

Abbreviations

CA 15-3

Type

INDIVIDUAL TEST

Results

RESULTS READY/ REPORTED IN 2 DAYS

Method

IMMUNOASSAY

Temp

ROOM TEMPERATURE

Setup

DAILY

Components Parameters

NOT APPLICABLE

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

NO PREPARATION REQUIRED

Sample type

SERUM

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 2ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

CENTRIFUGE SST (SERUM GEL TUBES) WITHIN 1-2 HOURS OF COLLECTION. CENTRIFUGE RED TOP VACUTAINERS AND ALIQUOT SERUM WITHIN 1-2 HOURS OF COLLECTION. THE SEPARATION VIAL MUST BE LABELED WITH AT LEAST 2 PATIENT IDENTIFIERS AND THE SAMPLE TYPE.

Reference intervals

APPROPRIATE VALUES ARE PROVIDED ON THE REPORT.

Clinical Utility

MONITORING TREATMENT RESPONSE, DISEASE PROGRESSION & ASSESSING RECURRENCE IN BREAST CANCER. LEVELS MAY ALSO BE ELEVATED IN OTHER CANCERS E.G. PANCREATIC, LUNG, ENDOMETRIAL, OVARIAN, CERVICAL, COLON, LIVER ETC.

Test Limitations/ Confounders

IMMUNOASSAY INTERFERENCE CAN GIVE RISE TO SPURIOUS RESULTS. SUCH INTERFERENCE CAN ARISE FROM PRESENCE OF HETEROPHILE ANTIBODIES, ANTI-ANIMAL ANTIBODIES, AUTOANTIBODIES, PARAPROTEINS, BIOTIN ETC. RESULTS SHOULD ALWAYS BE CORRELATED WITH CLINICAL FINDINGS.
11 Jun

CANCER ANTIGEN 125

vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

TUMOR MARKER

Synonyms/Aliases

CARBOHYDRATE ANTIGEN 125

Abbreviations

CA 125

Type

INDIVIDUAL TEST

Results

RESULTS READY/ REPORTED IN 3-4 HRS

Method

IMMUNOASSAY

Temp

ROOM TEMPERATURE

Setup

BATCHED.

Components Parameters

NOT APPLICABLE

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

NO PREPARATION REQUIRED

Sample type

SERUM

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 2ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

CENTRIFUGE SST (SERUM GEL TUBES) WITHIN 1-2 HOURS OF COLLECTION. CENTRIFUGE RED TOP VACUTAINERS AND ALIQUOT SERUM WITHIN 1-2 HOURS OF COLLECTION. THE SEPARATION VIAL MUST BE LABELED WITH AT LEAST 2 PATIENT IDENTIFIERS AND THE SAMPLE TYPE.

Reference intervals

APPROPRIATE VALUES ARE PROVIDED ON THE REPORT.

Clinical Utility

MONITORING TREATMENT RESPONSE, DISEASE PROGRESSION & ASSESSING RECURRENCE IN OVARIAN CANCER. LEVELS MAY ALSO BE ELEVATED IN OTHER CANCERS E.G. PANCREATIC, UTERINE CANCERS ETC.

Test Limitations/ Confounders

LEVELS MAY BE ELEVATED IN MULTIPLE BENIGN CONDITIONS E.G. ENDOMETRIOSIS, BENIGN OVARIAN CYSTS, HYPOTHYROIDISM, LIVER CIRRHOSIS, HEART FAILURE, NON-TUMORAL ASSAYS ETC. IMMUNOASSAY INTERFERENCE CAN GIVE RISE TO SPURIOUS RESULTS. SUCH INTERFERENCE CAN ARISE FROM PRESENCE OF HETEROPHILE ANTIBODIES, ANTI-ANIMAL ANTIBODIES, AUTOANTIBODIES, PARAPROTEINS, BIOTIN ETC. RESULTS SHOULD ALWAYS BE CORRELATED WITH CLINICAL FINDINGS.
11 Jun

C1 ESTERASE INHIBITOR

vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

IMMUNE

Synonyms/Aliases

C1 INACTIVATOR

Abbreviations

C1-INH

Type

INDIVIDUAL TEST

Results

RESULTS READY/ REPORTED IN 5 WORKING DAYS

Method

NEPHELOMETRY

Temp

FROZEN PREFERRED OR REFRIGERATED. AMBIENT (ROOM) TEMPERATURE NOT ACCEPTABLE.

Setup

BATCHED.

Components Parameters

NOT APPLICABLE

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. AGE, LMP IS REQUIRED.

Patient preparation

NO PREPARATION REQUIRED.

Sample type

SERUM

Sample volume

AT LEAST 2ML.

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

CENTRIFUGE SST (SERUM GEL TUBES) WITHIN 1-2 HOURS OF COLLECTION. CENTRIFUGE RED TOP VACUTAINERS AND ALIQUOT SERUM WITHIN 1-2 HOURS OF COLLECTION. THE SEPARATION VIAL MUST BE LABELED WITH AT LEAST 2 PATIENT IDENTIFIERS AND THE SAMPLE TYPE.

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

DIAGNOSING HEREDITARY ANGIOEDEMA (HAE) & MONITORING TREATMENT RESPONSE.

Test Limitations/ Confounders

TEMPERATURE SENSITIVE ANALYTE. LEVELS RISE IN ACUTE PHSE REACTIONS.
11 Jun

BETA HUMAN CHORIONIC GONADOTROPIN, SERUM

vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

ENDOCRINE; TUMOR MARKER

Synonyms/Aliases

BETA HCG

Abbreviations

ß HCG

Type

INDIVIDUAL TEST

Results

RESULTS READY/ REPORTED IN 3 HOURS

Method

IMMUNOASSAY

Temp

REFRIGERATED

Setup

DAILY

Components Parameters

NOT APPLICABLE

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. AGE, LMP IS REQUIRED.

Patient preparation

NO PREPARATION REQUIRED.

Sample type

SERUM

Sample volume

AT LEAST 2ML.

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

CENTRIFUGE SST (SERUM GEL TUBES) WITHIN 1-2 HOURS OF COLLECTION. CENTRIFUGE RED TOP VACUTAINERS AND ALIQUOT SERUM WITHIN 1-2 HOURS OF COLLECTION. THE SEPARATION VIAL MUST BE LABELED WITH AT LEAST 2 PATIENT IDENTIFIERS AND THE SAMPLE TYPE.

Reference intervals

AGE, GENDER, PREGNANCY STATUS, WEEKS OF PREGNANCY (AS APPROPRIATE) ARE PROVIDED ON THE REPORT.

Clinical Utility

CONFIRM PREGNANCY, DETERMINE THE APPROXIMATE AGE OF THE FETUS, DIAGNOSE AN ABNORMAL PREGNANCY SUCH AS AN ECTOPIC PREGNANCY, DIAGNOSE A POTENTIAL MISCARRIAGE.

Test Limitations/ Confounders

IMMUNOASSAY INTERFERENCE CAN GIVE RISE TO SPURIOUS RESULTS. SUCH INTERFERENCE CAN ARISE FROM PRESENCE OF HETEROPHILE ANTIBODIES, ANTI-ANIMAL ANTIBODIES, AUTOANTIBODIES, PARAPROTEINS, BIOTIN ETC. RESULTS SHOULD ALWAYS BE CORRELATED WITH CLINICAL FINDINGS. IF INTERFERENCE IS SUSPECTED, URINE HCG (URINE PDT) TESTING SHOULD BE CONSIDERED.
09 Jun

BENCE JONES PROTEIN, QUALITATIVE, URINE

vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

TUMOR MARKER

Synonyms/Aliases

- N/A

Abbreviations

BJP

Type

INDIVIDUAL TEST

Results

RESULTS READY/ REPORTED IN 3 HOURS

Method

BRADSHAW TEST

Temp

ROOM TEMPERATURE OR REFRIGERATED.

Setup

DAILY

Components Parameters

NOT APPLICABLE

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. URINE PROTEIN ELECTROPHORESIS IS PREFERRED OVER BRADSHAW TEST FOR BENCE JONES PROTEIN.

Patient preparation

EARLY MORNING URINE SAMPLE PREFERRED.

Sample type

EARLY MORNING URINE SAMPLE PREFERRED.

Container/ preservative

URINE BOTTLE PROVIDED BY THE LAB.

Sample volume

10MLSPOT OR 24HOUR URINE

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

IT IS PREFERRED TO DO URINE PROTEIN ELECTROPHORESIS IN PLACE OF "BENCE JONES PROTEIN" SPOT TEST. ORDER MAY BE SUBSTITUTED.

Reference intervals

NEGATIVE

Clinical Utility

DIAGNOSE & MONITOR PATIENTS WITH MONOCLONAL GAMMOPATHIES E.G. MULTIPLE MYELOMA. FOR QUALITATIVE DETECTION OF KAPPA & LAMBDA LIGHT CHAINS.

Test Limitations/ Confounders

-N/A
09 Jun

ANTIMULLERIAN HORMONE

vincentochiengde

Category

SPECIAL CHEMISTRY.

Sub Category

ENDOCRINE

Synonyms/Aliases

ANTI-MULLERIAN HORMONE; MULLERIAN INHIBITING FACTOR; MULLERIAN INHIBITING HORMONE; MULLERIAN INHIBITING SUBSTANCE

Abbreviations

AMH; MIF; MIH; MIS

Type

INDIVIDUAL TEST

Results

RESULTS READY/ REPORTED IN 3 HOURS

Method

IMMUNOASSAY

Temp

REFRIGERATED

Setup

BATCHED.

Components Parameters

NOT APPLICABLE

PRE-ANALYTIC CONSIDERATIONS

Test Ordering Instructions

FILL OUT TEST REQUEST FORM FULLY & LEGIBLY.

Patient preparation

NO PREPARATION REQUIRED (NOT DEPENDENT ON MENSTRUAL CYCLE PHASE).

Sample type

SERUM. HEPARIN PLASMA IS AN ACCEPTABLE ALTERNATE SPECIMEN.

Container/ preservative

SERUM SEPARATOR TUBE (SST/ GEL) OR PLAIN (RED TOP) VACUTAINER.

Sample volume

AT LEAST 3ML

Rejection criteria

LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE.

Other Instructions

CENTRIFUGE SST (SERUM GEL TUBES) WITHIN 1-2 HOURS OF COLLECTION. CENTRIFUGE RED TOP VACUTAINERS AND ALIQUOT SERUM WITHIN 1-2 HOURS OF COLLECTION. THE SEPARATION VIAL MUST BE LABELED WITH AT LEAST 2 PATIENT IDENTIFIERS AND THE SAMPLE TYPE.

Reference intervals

INTERPRETIVE DATA IS PROVIDED ON THE REPORT.

Clinical Utility

ASSESSMENT OF OVARIAN RESERVE/ FERTILITY POTENTIAL E.G. IN PATIENTS SUSPECTED TO HAVE PREMATURE OVARIAN FAILURE OR UNDERGOING ASSISTED REPRODUCTION / IVF. ASSESSMENT OF AMBIGUOUS GENITALIA AND OTHER DISORDERS OF SEXUAL DEVELOPMENT (DSD). MALE FERTILITY ASSESSMENT. LEVELS MAY BE INCREASED IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS).

Test Limitations/ Confounders

IMMUNOASSAY INTERFERENCE CAN GIVE RISE TO SPURIOUS RESULTS. SUCH INTERFERENCE CAN ARISE FROM PRESENCE OF HETEROPHILE ANTIBODIES, ANTI-ANIMAL ANTIBODIES, AUTOANTIBODIES, PARAPROTEINS, BIOTIN ETC. RESULTS SHOULD ALWAYS BE CORRELATED WITH CLINICAL FINDINGS.
1 2 3 4 5 6 … 8
Call us for any questions +254 722 149 505

© GTB Scanlab Nakuru Ltd. Developed by Butterfly Prime Solutions